Lakewood-Amedex Biotherapeutics Inc. (LABT) Key Metrics
LABT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.4M
- Enterprise value
- −$265,061
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
LABT key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLABT returns How much profit the business earns on the capital it uses.
LABT per-share figures Results divided by the shares outstanding at year-end.
LABT financial health Debt, liquidity and how easily interest is covered.
LABT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LABT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LABT cash returned to shareholders
LABT key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Per share | |||
| Revenue per share | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.76 | −$6.94 | −$11.84 |
| Operating cash flow per share | −$1.40 | −$8.18 | −$9.74 |
| Free cash flow per share | −$1.40 | −$8.18 | −$9.74 |
| Cash per share | $0.17 | $0.97 | $3.62 |
| Book value per share | −$1.41 | $0.59 | $6.52 |
| Tangible book value per share | −$1.41 | $0.59 | $6.52 |
| Capex per share | $0.00 | $0.00 | $0.00 |
| Debt per share | $1.19 | — | — |
| Shares outstanding | 1.4M | 700K | 700K |
| Change in shares outstanding | +99.2% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | — | −195.5% | −181.7% |
| Return on invested capital (ROIC) | — | — | −336.3% |
| Return on assets (ROA) | −495.8% | −121.9% | −120.1% |
| Return on tangible assets | −798.9% | −453.5% | −120.1% |
| Financial health | |||
| Total debt | $1.7M | — | — |
| Cash & short-term investments | $236,400 | $681,098 | $2.5M |
| Net debt | $1.4M | −$681,098 | −$2.5M |
| Debt / assets | 3.45 | — | — |
| Current ratio | 0.13 | 1.55 | 3.14 |
| Quick ratio | 0.13 | 1.55 | 3.14 |
| Interest coverage | -37.4 | -805.4 | -863.7 |
| Working capital | −$2.1M | $273,353 | $4.4M |
| Invested capital | −$540,596 | −$271,487 | $2.0M |
| Tangible asset value | −$2.0M | $409,611 | $4.6M |
| Net current asset value | −$2.1M | $113,011 | $4.1M |
| Graham net-net per share | −$1.59 | $0.03 | $0.28 |
| Capital allocation | |||
| Share buybacks (net) | $0 | $50,000 | $0 |
| Capex / depreciation | 0.00 | 0.02 | 0.00 |
| Efficiency | |||
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average payables | $273,754 | $332,766 | $499,066 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from LABT's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LABT valuation and financial ratios
It ended the year with $1.7 million of debt and $0.2 million in cash and short-term investments, net debt of $1.4 million.
See the LABT income statement, the LABT chart for price history, or the LABT stock overview for the latest quote and news.
LABT key metrics FAQ
How much debt does Lakewood-Amedex Biotherapeutics have?
Lakewood-Amedex Biotherapeutics had total debt of $1.7 million at the end of fiscal 2025.
What is Lakewood-Amedex Biotherapeutics's current ratio?
Lakewood-Amedex Biotherapeutics's current ratio was 0.13 at the end of fiscal 2025: current assets were 0.13 times current liabilities.